Abstracts tagged "interleukins (IL)"

Abstract Number: 2879 • 2014 ACR/ARHP Annual Meeting
Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β-Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh¹, Sharayah Riegsecker², Sadiq Umar¹ and Salahuddin Ahmed¹, ¹Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, ²Department of Pharmacology, University of Toledo, Toledo, OH
Background/Purpose: In rheumatoid arthritis (RA), the role of interleukin-1β (IL-1β) signaling proteins (IRAK-1/TAK-1/TRAF-6) proximal to IL-1 receptor in mediating proinflammatory response is not completely understood.…
Abstract Number: 665 • 2014 ACR/ARHP Annual Meeting
Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Jing He¹, Xia Zhang², Xiaolin Sun³, Jianping Guo³, Yunbo Wei⁴, Zhaohua Hou⁴, Yu Di⁵ and Zhanguo Li³, ¹Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁴Immunology for Environment and Health, Shandong Analysis and Test Center, Shandong Academy of Science, Shandong, China, ⁵Molecular Immunomodulation Laboratory, Monash University, Clayton, Austria
Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to nuclear self-antigens, production of pathogenic autoantibodies and damage tomultiple organs.…
Abstract Number: 2837 • 2014 ACR/ARHP Annual Meeting
Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE
Jens Y. Humrich¹, Caroline von Spee-Mayer¹, Elise Siegert¹, Angelika Rose¹, Tobias Alexander², Falk Hiepe¹, Andreas Radbruch³, Gerd Burmester⁴ and Gabriela Riemekasten¹, ¹Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ³German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, ⁴Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 322 • 2014 ACR/ARHP Annual Meeting
Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer¹, Rambon Shamilov¹, Caroline Stremnitzer¹, Katie Matthews¹, Michael Fisher¹, William Windsor¹, James Blinn¹, Ellen M. Ginzler³ and Jefferson Tilley¹, ¹Innovimmune Biotherapeutics, Brooklyn, NY, ²SUNY-Downstate Medical Center, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: T helper 17 [TH17] cells and its production of TH17 cytokines IL-17A and IL-17F play a critical role in the pathogenesis of RA and…
Abstract Number: 2168 • 2014 ACR/ARHP Annual Meeting
Extramedullary Myelopoiesis Drives Persistent Toll-like Receptor-Mediated Inflammation
Lehn K. Weaver¹ and Edward M. Behrens², ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Many rheumatic diseases are driven by chronic, repeated activation of Toll-like receptors (TLR) causing the initiation and perpetuation of disease. However, TLR-activated innate immune…
Abstract Number: 311 • 2014 ACR/ARHP Annual Meeting
Inhibition of Natural Killer (NK) Cell Cytotoxicity By Interleukin-6 (IL-6): Implications for the Pathogenesis of Macrophage Activation Syndrome
Loredana Cifaldi¹, Giusi Prencipe², Ivan Caiello², Claudia Bracaglia², Raffaele Strippoli³ and Fabrizio De Benedetti Sr.², ¹Paediatric Haematology/Oncology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ²Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ³Cellular Biotechnologies and Haematology, Sapienza Rome University, Rome, Italy
Background/Purpose: MAS occurs frequently in patients with active systemic juvenile idiopathic arthritis(s-JIA) and because of the similarities with Haemophagocytic Lymphohistiocytosis (HLH) is classified among secondary…
Abstract Number: 2039 • 2014 ACR/ARHP Annual Meeting
Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi-Years before Clinical Onset (Pre-RA) Than in Non-RA Matched Control (CN) Subjects
Alfonse T. Masi, Azeem A. Rehman and Jean C. Aldag, Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Dysregulations in androgenic-anabolic (A-A) steroids and cytokines are recognized in RA and pre-RA subjects (Rheum Dis Clin N Am 2005; 31: 131-60). However, deviations…
Abstract Number: 81 • 2014 ACR/ARHP Annual Meeting
Elevated Peripheral Blood Leukocyte Inflammatory Gene Expression in Radiographic Progressors with Symptomatic Knee Osteoarthritis: NYU and OAI Cohorts
Mukundan Attur¹, Alexander Statnikov², Svetlana Krasnokutsky Samuels¹, Virginia B. Kraus³, Joanne Jordan⁴, Braxton D. Mitchell⁵, Michelle Yau⁶, Jyoti Patel¹, Constantin F. Aliferis², Marc C. Hochberg⁷, Jonathan Samuels¹ and Steven B. Abramson⁸, ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Center for Health Informatics and Bioinformatics, NYU Langone Medical Center, New York, NY, ³Medicine/Rheumatology, Duke University Medical Center, Durham, NC, ⁴Thurston Arthritis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Departments of Medicine and Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD, ⁶Epidemiology and Public Health, University of Maryland, Baltimore,, MD, ⁷Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁸Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY
Background/Purpose: We and others have demonstrated low grade inflammation exists in OA joint tissues, where it may contribute to disease pathogenesis. In the current studies…
Abstract Number: 1816 • 2014 ACR/ARHP Annual Meeting
Toll-like Receptor 4-Induced Interleukin-1 Defines the Intestinal Microbiome and Mucosal Immune Response in Arthritis-Prone IL-1 Receptor Antagonist Deficient Mice
Tom Ederveen¹, Rebecca Rogier², Jos Boekhorst¹, Harm Wopereis³, Johan Garssen³, Sacha van Hijum¹, Fons A.J. van de Loo², Marije I. Koenders², Wim B. van den Berg² and Shahla Abdollahi-Roodsaz⁴, ¹Centre for Molecular Bioinformatics Nijmegen (CMBI), Radboud university medical center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Danone Research, Wageningen, Netherlands, ⁴Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose Interleukin-1 (IL-1) plays a pivotal role in inflammation and autoimmunity. Mice deficient in the IL-1 receptor antagonist (IL-1Ra-/-) spontaneously develop a T cell-driven autoimmune…
Abstract Number: 1746 • 2014 ACR/ARHP Annual Meeting
Involvement of IL-17-Producing MAIT Cells in the Pathogenesis of Rheumatoid Arthritis
Eri Hayashi¹, Asako Chiba², Mie Kitagaichi³, Kurisu Tada³, Ken Yamaji⁴, Naoto Tamura¹, Yoshinari Takasaki³ and Sachiko Miyake², ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are a subset of innate-like lymphocytes which are restricted by the MHC-related molecule-1 (MR1) and express a semi-invariant TCRα…
Abstract Number: 1732 • 2014 ACR/ARHP Annual Meeting
Attenuation of Sclerodermatous Graft Versus Host Disease (sclGVHD) in IL4RA Receptor-Deficient Mice
Katia Urso¹, Kelly Tsang², Robert Lafyatis³ and Antonios O. Aliprantis², ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose Scleroderma is a rare autoimmune disease characterized by the accumulation of fibrotic tissue in multiple organs including the skin, gut and lungs. To date,…
Abstract Number: 931 • 2013 ACR/ARHP Annual Meeting
Effect Of Neutralizing IL-17A and IL-17F Antibodies On Host Resistance To Acute Mycobacterium Tuberculosis Infection In Mice In Comparison With Neutralizing TNF-α Treatment
Michael Kammüller¹, Franco Di Padova², Christian Antoni³, Salah-Dine Chibout⁴, Timothy Wright⁵, Marie-Laure Bourigault⁶, Noria Segueni⁶, Stephanie Rose⁶, Bernhard Ryffel⁶ and Valerie Quesniaux⁶, ¹PCS - Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland, ²Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Institutes for Biomedical Research, Basel, Switzerland, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶UMR7355 CNRS and University of Orleans, Orleans, France
Background/Purpose: Antibodies targeting IL-17A or IL-17RA are in clinical trials for the treatment of several autoimmune diseases. However, these therapies, by blocking critical mediators of…
Abstract Number: 940 • 2013 ACR/ARHP Annual Meeting
Novel Function Of Soluble Interleukin-6 Receptor As An Antagonist Of Interleukin-27-Mediated Anti-Inflammatory Responses
Misato Hashizume¹, Keiko Esaki², Keiko Yoshimoto³, Hideto Kameda³, Tsutomu Takeuchi³ and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Discovery Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The immunological roles of interleukin 27 (IL-27) have been reported in various rheumatic diseases, such as rheumatoid arthritis (RA), lupus, systemic sclerosis and psoriasis.…
Abstract Number: 943 • 2013 ACR/ARHP Annual Meeting
Synergism Between Granulocyte-Macrophage Colony Stimulating Factor and Interleukin-17 Causes Joint Damage Via The Production Of Interleukin-23, Receptor Activator Of NF-κB Ligand and S100A8
Annemarie E.M. Van Nieuwenhuijze¹, Fons A.J. Van de Loo², Birgitte Walgreen³, Miranda B. Bennink⁴, Monique M. Helsen³, Liduine Van den Bersselaar¹, Ian P. Wicks^5,6, Wim B. Van den Berg⁷ and Marije I. Koenders⁷, ¹Rheumatology and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, Australia, ⁶Department of Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ⁷Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: T helper-17 (Th17) cells are important mediators of inflammatory diseases, and are the main pathogenic cell type in many animal models of autoimmunity. Recent…
Abstract Number: 2801 • 2013 ACR/ARHP Annual Meeting
Comparative Longitudinal Analysis Of Periarticular Bone Structure In Patients Treated With Methotrexate In Combination Of Either TNF Blockers Or Tocilizumab
Sebastian Kraus¹, Matthias Englbrecht¹, Juergen Rech², Roland Kocijan¹, Georg A. Schett¹ and Stephanie Finzel¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Inhibition of tumor necrosis factor alpha (TNFi) and interleukin-6 receptor (IL6Ri, tocilzumab) are among the most potent therapeutic strategies in patients with rheumatoid arthritis…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.